Skip to main content
OpenTrials

Clinical trial condition

Adnexal Diseases

Explore clinical trials studying Adnexal Diseases. Study availability and eligibility vary by location and protocol.

3,504 public trials 677 recruiting studies
Refine in advanced search Browse all conditions

Adnexal Diseases trial results

Active, Not Recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01167712

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +50 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 564 locations
View Trial Details
Active, Not Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640

Conditions
Adnexal Diseases, Biliary Tract Diseases, Biliary Tract Neoplasms, +36 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • USC Norris Cancer Hospital Los Angeles, California, United States
  • Chao Family Comprehensive Cancer Ctr. Orange, California, United States
  • Yale-New Haven Hospital New Haven, Connecticut, United States
View all 49 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479

Conditions
Adnexal Diseases, Advanced Solid Tumor, Bladder Cancer, +72 more
Locations
  • AdventHealth Orlando Orlando, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 28 locations
View Trial Details
Active, Not Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumor, +60 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • UC Irvine Cancer Center Orange, California, United States
  • UC Davis Cancer Center Sacramento, California, United States
  • UCSF San Francisco, California, United States
View all 64 locations
View Trial Details

Related conditions